Anti-neoplastic urinary protein

Drug Profile

Anti-neoplastic urinary protein

Alternative Names: ANUP; Human anti-neoplastic urinary protein

Latest Information Update: 17 Jan 2011

Price : $50

At a glance

  • Originator Antitumor Research Products
  • Developer TranXenoGen
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 17 Jan 2011 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 19 Feb 2007 Preclinical development is ongoing
  • 18 Nov 2003 ANUP peptides are available for licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top